The cell line is not submitted yet.
(only basic data is shown)
General
Cell Line |
|
| hPSCreg name | SCTi007-A |
| Cite as: | SCTi007-A |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 18th April 2026 |
| Notes | Early-Onset Parkinson’s Disease Human iPSC Line, Male, SCTi007-A was derived from peripheral blood mononuclear cells (PBMCs) of a 50-year-old donor clinically diagnosed with Parkinson’s disease (PD), with symptom onset at age 48. As defined by Mehanna et al. (2022), early-onset Parkinson's disease has an age at onset between 21 and 50 years. This line was reprogrammed using a non-integrating method to ensure genomic integrity and reproducibility. Comprehensive quality control testing confirmed karyotypic stability, pluripotency marker expression, and trilineage differentiation potential. This PD human induced pluripotent stem cell (hiPSC) line serves as a robust human-relevant model for studying disease mechanisms associated with neurodegeneration, dopaminergic neuron vulnerability, and aging-related cellular pathways. It is manufactured with mTeSR™ Plus (Catalog #100-0276) and ReLeSR™ (Catalog #100-0483), and it provides a valuable tool for investigating pathogenic mechanisms, identifying biomarkers, and developing novel therapeutic strategies for PD. |
| User feedback | |
Provider |
|
| Generator |
STEMCELL Technologies Inc. (SCT)
Contact:
STEMCELL Technologies Inc. (SCT) |
| Owner | STEMCELL Technologies Inc. (SCT) |
| Distributors | |
External Databases |
|
| BioSamples | SAMEA120790197 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Additional restrictions:
For in vitro research use only. Not approved for diagnostic, therapeutic, or clinical applications. Not approved for human or veterinary use in vivo. |
hIPSC Derivation
General |
Login to share your feedback, experiences or results with the research community.